1 / 40

T2DM: NICE Guidelines

T2DM: NICE Guidelines. Dr Nemanja Stojanovi ć Consultant Endocrinologist Queen’s Hospital, Romford. The Talk. Diabetes: Definition/ Classification A few cases NICE Guidelines New Developments. Definition. Fasting plasma glucose 7mmol/l- 2 occasions

keene
Télécharger la présentation

T2DM: NICE Guidelines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. T2DM: NICE Guidelines Dr Nemanja Stojanović Consultant Endocrinologist Queen’s Hospital, Romford

  2. The Talk • Diabetes: Definition/ Classification • A few cases • NICE Guidelines • New Developments

  3. Definition • Fasting plasma glucose 7mmol/l- 2 occasions • 2 h plasma glucose or random glucose of 11.1 mmol/l

  4. Case1: What is Your Next Question ? • Is there family history of Diabetes? • She should be referred and genetic counselling offered

  5. DM Classification • Type 1 DM • Type 2 DM • GDM • ? Double Diabetes • Type 1.5 • LADA • Other subtypes

  6. MODY HNF-4α (1) Glucokinase (2) HNF-1α (3) IPF1  (4) HNF-1β (5) Neuro D1 (6) Neonatal Diabetes Mitochondrial DNA defects Genetic defects of insulin action Genetic Diabetes

  7. Drug Induced • Steroids • Pentamidine • T4 • β blockers • Dizoxide • Nicotinic Acid • Thiazides • α Interferon

  8. ENDOCRINOPATHIES Acromegaly Cushing’s Disease Glucagonoma Hyperthyroidism Somatostatinoma Aldosteronoma Pheochromocytoma Others Exocrine Pancreas Cystic Fibrosis Hemochromatosis Haemosiderosis Cancer Trauma/ surgery Pancreatitis Other Forms of DM

  9. NICE May 08 • Patient centred care • Good communication is essential • Support the care with evidence based medical information • Allow patient is to reach informed decisions about their care

  10. Self Monitoring • Offer it only as a part of integral care • Discuss the purpose • Insulin treatment • OHA’s: to provide information on hypoglycaemia • To assess changes in glucose control resulting from medications and lifestyle change • To monitor glucose during intercurrent illness • To ensure safety during activities, including driving.

  11. Education • Meet the national criteria laid down by DoH • Meet the local cultural, linguistic, cognitive and literacy needs • Provide appropriate resources to support the educators, who should be properly trained and allowed time to develop and maintain their skills.

  12. Diet • General advice for healthy eating: • Include high-fibre, low-glycaemic index sources of carbohydrate • Include low-fat dairy products and oily fish • Control the intake of foods containing saturated fats and trans fatty acids

  13. HbA1c • Target: 6.5% • Discuss with the patient appropriate levels, set individual A1c targets • Escalate treatment when HbA1c is> 7.5%

  14. Metformin • Start over several weeks • Consider SR if GI side effects • Stop if Cr> 150umol/l or GFR< 30ml/min • In patient with moderate liver impairment /cardiac dysfunction discuss with the patient risk vs benefit

  15. Sulphonylureas • Start low cost (not glibenclamide) when indicated • Educate about the risk of hypoglycaemia • PPGs

  16. Glitazones • Warn about significant oedema and tell the person what to do if it happens • Do not start if evidence of LVF or high risk of fracture • When selecting a glitazone take into account most up-to-date advice, safety and cost issues

  17. Exenatide • HbA1c> 7.5% • BMI (Caucasian)> 35 • Has specific psychological, biochemical or physical problems arising from high body weight • Would otherwise be starting TZD or insulin. • Continue if of 1% in A1c over 6 months and BW of 5% over 12 months

  18. Acarbose • If unable to tolerate other medications

  19. Insulin • If HbA1c> 7.5% • Structured programme • Start once or twice daily NPH with SU + metformin • Injection devices/ sharps

  20. Glargine • Patients who need help injecting • BD insulin otherwise needed • Significant hypoglycaemia including nocturnal hypos

  21. Biphasic Insulin • HbA1c > 9.0%. Biphasic Analogues • Immediate injection before the meals is preferred • Problems with hypos • Postprandial hyperglycaemia is a problem

  22. Blood Pressure • Target 140/80 mmHg • If macro/ microvascular damage: retinopathy, nephropathy, cerebrovascular disease: 130/80 mmHg • Monitor for SE of therapy

  23. Blood Pressure • Monitor annually in normotensive patients without renal disease • BP above the target: • Repeat within a month if > 150/90mmHg • Repeat within 2 months if > 140/80mmHg - Repeat within 2 months if > 130/80mmHg & eye, kidney or cerebrovascular disease

  24. Patients Not at High CVS Risk • Normal weight • BP< 140/80mmHg off treatment • Normal ACR/ AER • Non smokers • Do not have high risk lipid profile • No PMH of CVH • No FH of CVD DO NOT HAVE ANY OF THESE

  25. Effect of reduction of LDL by 1mmol/l by any means on coronary death and non-fatal MI: meta-analysis of 58 trials Law MR BMJ 2003, 326: 1423-9

  26. Equivalent Doses + max dose decreases the LDL by additional 20%

  27. Nephropathy • Assess annually: ACR, Cr • High ACR: repeat 2x within 3-4 months • Treat with ACE/ ARB • Aim for BP< 130/80mmHg

  28. Suspect Intrinsic Renal Disease • No retinopathy • BP resistant to treatment • Proteinuria in the face of previously normal ACR • Rapid decline in ACR • Haematuria • Systemically ill patient

  29. Eye Screening • Annually • Discuss the benefits • Tropicamide and Driving

  30. Referral to Ophthalmologist • Maculopathy • Unexplained loss of VA • Pre-proliferative retinopathy

  31. Studies/ Recommendations that followed the Guideline

  32. ADVANCE • 11140 patients: 5 years • Intensive glycaemic control (A1c 6.5%) vs Conventional (A1c 7.3%) • Intensive group: gliclazide MR 30 to 120 mg daily and other hypoglycamic agents including insulin N Engl J Med 2008;10.1056/NEJMoa0802987

  33. ADVANCE Primary Endpoints • Composite of macro and microvascular events considered jointly and separately • Macro: CVD death, non fatal CVA & MI • Micro:new or worsening nephropathy ; doubling of the serum creatinine; the need for dialysis; death due to renal causes; worsening of retinopathy N Engl J Med 2008;10.1056/NEJMoa0802987

  34. ADVANCE Conclusion • The main contributor to the 10% relative reduction in the primary outcome found with intensive control as compared with standard control was a 21% relative reduction in the risk of new or worsening nephropathy • More modest but significant reduction in microalbuminura

  35. ACCORD Trial • 10,251 patients • Intensive glycaemic control and CVS outcomes • Primary outcomes : CVD death, Non fatal CVA & MI • Intensive Treatment: HbA1c< 6% • Conventional Treatment HbA1c 7-7.9 • Death rates begin to separate after 1 year….. N Engl J Med 2008;10.1056/NEJMoa0802743

  36. ACCORD N Engl J Med 2008;10.1056/NEJMoa0802743

  37. HbA1c and Screening for T2DM • <6% • 6.1-6.5% • 6.5-6.9% • >7% JCEM,2008; 93: 2447-53

  38. Fasting Plasma Glucose and CVA/ Vascular Events: NOMAS • 3298 participants • 572 patients with DM • DM patients: 338 elevated FPG > 7mmol/l • In elevated FPG: CVA HR 2.7(95 CI: 2.0-3.8) • Those with DM and normal FPG were not at increased risk Dia Care 2008; 31:1132- 37

  39. Conclusion • A1c 6.5% ( ? 7.5%) • BP 130/80mmHg (140/8o mmHg) • Cholesterol 4mmol/l • LDL 2mmol/l • Triglycerides 4.5mmol/l • Eyes, Kidneys, Nerves: Screen annually

  40. EndoDiabetes.com

More Related